Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

October 11, 2022

Rallybio reports positive results in study of drug for newborn ailment

PHOTO | Steve Laschever Rallybio’s co-founders (from left to right) are: Dr. Stephen Uden, Jeffrey Fryer and Martin Mackay.
By Liese Klein

New Haven’s Rallybio reported promising results in a Phase 1 study of its drug candidate RLYB212, designed for the prevention of a serious blood disease in fetuses and newborns. 

A monoclonal antibody, RLYB212 can prevent the development of fetal and neonatal alloimmune thrombocytopenia, a potentially fatal rare disease that can cause uncontrolled bleeding due to immune incompatibility between maternal and fetal platelets.

The study found that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused disease-causing platelets more rapidly compared to a placebo. The study is being conducted at the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Germany.

Rallybio CEO Martin Mackay said, “We are pleased to see rapid and complete elimination of transfused platelets in all subjects to date… consistent with our proof-of-concept criteria.”

The preliminary results showed acceptable safety and tolerability with no serious adverse events, the company said in a statement. 

Rallybio most recently made news in May when it purchased a Sanofi drug candidate with potential as a treatment for severe anemia.

Contact Liese Klein at lklein@newhavenbiz.com.

Sign up for Enews

Most Recent

Most Recent

0 Comments

Order a PDF